Business Context and Reporting Period
Company: pSivida Corp. (Note: Input metadata referenced "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2011
Business Overview: pSivida develops sustained-release drug delivery products for chronic eye diseases using Durasert and BioSilicon technologies. The company is currently focused on the regulatory review of ILUVIEN (licensed to Alimera Sciences) for diabetic macular edema (DME) and the development of a latanoprost implant (in collaboration with Pfizer).
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2011 | Three Months Ended Sep 30, 2010 |
|---|---|---|
| Total Revenues | $1,659,000 | $476,000 |
| Net Loss | $(2,427,000) | $(3,108,000) |
| Loss Per Share (Basic & Diluted) | $(0.12) | $(0.17) |
| Operating Cash Flow | $(2,660,000) | $(2,219,000) |
| Cash & Cash Equivalents (Sep 30, 2011) | $9,811,000 | N/A |
| Marketable Securities (Sep 30, 2011) | $11,460,000 | N/A |
| Total Liquidity (Cash + Securities) | $21,271,000 | N/A |
| Accumulated Deficit | $(229,350,000) | N/A |
Debt: The company reported no borrowings or line of credit facilities as of September 30, 2011. Total liabilities were $7,908,000, primarily consisting of deferred revenue ($6,424,000) and accrued expenses.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 249% to $1.66 million. This was driven by a $1.1 million one-time recognition of deferred revenue from the termination of the Intrinsiq license agreement and $288,000 in revenue from the amended Pfizer agreement.
- Royalty Decline: Royalty income from Bausch & Lomb (Retisert/Vitrasert) decreased to $198,000 from $402,000 in the prior year.
- Operating Expenses: Total operating expenses rose 7% to $4.19 million. Research and Development (R&D) expenses increased 22% to $2.13 million due to clinical trial costs for the Latanoprost product. General and Administrative (G&A) expenses decreased 5% to $2.06 million due to lower professional fees.
- Net Loss Improvement: Net loss narrowed by 22% to $2.43 million, primarily due to the significant revenue recognition mentioned above.
- Derivative Income: Income from the change in fair value of derivatives dropped to $42,000 from $338,000, largely due to the expiration of approximately 3.7 million A$-denominated warrants.
Outlook, Risks, and Management Commentary
- ILUVIEN Regulatory Status: The FDA issued a Complete Response Letter (CRL) in December 2010 regarding the NDA for ILUVIEN. Alimera resubmitted the NDA in May 2011 (Class 2 resubmission) with a PDUFA decision date of November 12, 2011. Alimera is conducting a Phase III physician utilization study to provide additional data requested by the FDA.
- Financial Outlook: Management anticipates capital resources of $21.3 million will fund operations into at least calendar year 2013. Future funding beyond 2012 is heavily dependent on FDA approval of ILUVIEN, which would trigger a $25.0 million milestone payment from Alimera.
- Pfizer Collaboration: The company is developing a latanoprost implant under an amended agreement. Pfizer holds an exclusive option to license the product for a $20.0 million payment plus royalties and milestones up to $146.5 million upon proof-of-concept.
- Risks: Key risks include the failure to obtain regulatory approval for ILUVIEN, the inability to commercialize products, dependence on collaboration partners, and the need for additional financing if milestones are not met. The company also faces foreign currency exposure (USD/GBP) and volatility in derivative liabilities.
Investor Verification Checklist
- ILUVIEN Approval Timeline: Verify the status of the FDA review and the November 12, 2011 PDUFA date, as this dictates the potential $25 million milestone.
- Revenue Sustainability: Confirm that the $1.1 million revenue from the Intrinsiq termination is a one-time event and assess the run-rate of revenue from the Pfizer agreement.
- Cash Burn Rate: Monitor the quarterly cash burn (approx. $2.7M operating cash outflow) against the $21.3M liquidity position to validate the "funding into 2013" assertion.
- Derivative Liability Exposure: Review the remaining A$-denominated warrants ($128k liability) and their sensitivity to stock price and currency fluctuations.
- Intangible Asset Amortization: Note the $833k quarterly amortization expense on intangible assets (Durasert and BioSilicon), which impacts net income but is non-cash.